BioCryst Pharmaceuticals (BCRX) said Tuesday that Chief Financial Officer Anthony Doyle intends to resign from the company, effective April 9.
BioCryst said Doyle's resignation is not the result of any disagreement with the company on any matter relating to operations, policies, or practices.
The company said it is now searching for a new CFO and that Doyle will remain in his role through April 9 to ensure a smooth transition.
BioCryst shares were down 3.6% in recent premarket trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。